AstraZeneca acquires antibiotic developer Novexel for $350 million in cash plus $75 million in post-deal milestones.
Arena Pharmaceuticals files an NDA for its obesity drug lorcaserin in December as anticipated, leaving analysts to ponder the firm's partnering potential in a treacherous regulatory, commercial and reimbursement landscape.
Novartis to pay $120 million for the private biotech Corthera plus up to $500 million in milestone payments; it gains relaxin in Phase III for acute decompensated heart failure.
Roche can launch Mircera 10 months before Amgen's EPO patent expires under licensing agreement between the two.
